Long‐term safety of replication‐defective smallpox vaccine (MVA‐BN) in atopic eczema and allergic rhinitis

ConclusionsA good safety profile of the MVA‐BN vaccine was shown. The absence of adverse events in subjects with atopic disorders appears promising for the development of a safe smallpox vaccine for patients with AE or other atopic diseases.

Source: Journal of the European Academy of Dermatology and Venereology - June 28, 2016 Category: Dermatology Authors: U. Darsow, M. Sbornik, S. Rombold, K. Katzer, F. Sonnenburg, H. Behrendt, J. Ring Tags: Original Article Source Type: research